

Contents

Antipsychotics: Chemistry (Structure and Effectiveness)

CHAPTER 1

Tricyclic Neuroleptics: Structure-Activity Relationships. J. SCHMUTZ and C.W. PICARD

A. Criteria for Neuroleptic Activity 3

B. Chemical Classification of the Tricyclic Neuroleptics 4

C. Molecular Conformation 4

D. Stereospecificity of Action 9

E. Nature of the Basic Side Chain 12

F. Aromatic Substitution 15

G. Nature of the Central Ring 18

H. Non-Cataleptogenic Neuroleptics 19

I. Conclusion 20

References 20

CHAPTER 2

Butyrophenones and Diphenylbutylpiperidines. P. A. J. JANSSEN and W.F.M. VAN BEVER. With 3 Figures

A. Introduction 27

B. Structure-Activity Relationships 28

 I. Chemistry 28

 II. Pharmacology 31

 III. Clinical Aspects 35

 1. Butyrophenones 35

 2. Diphenylbutylpiperidines 36

C. Conclusion 37

References 37

CHAPTER 3

Centrally Acting Rauwolfia Alkaloids. H.J. BEIN

A. Introduction and History 43

B. Biologic Fate and Mechanisms of Action of Reserpine 44

C. Central Actions of Reserpine	46
I. Effect of Reserpine on Behavior	46
II. Effect of Reserpine on the Motor System	48
III. Effects of Reserpine on Bioelectric Signals	50
D. Comparison with Other Neuroleptics	51
I. General Clinical Effects	51
II. Alleged Depression-Inducing Effect of Neuroleptics	52
References	52

CHAPTER 4

Behavioral Pharmacology of Antipsychotics. H. KREISKOTT

A. Introduction	59
B. Basic Aspects and Considerations in Regard to Investigations	59
C. Action of Antipsychotics on Spontaneous Behavior	61
I. Pattern of Action on Behavior	62
II. Locomotion	62
III. Immobilization	64
IV. Muscle Relaxation and Ptosis	65
V. Excitation Conditions	66
VI. Aggression	67
VII. Reproduction	69
VIII. Maternal Behavior	69
IX. Feeding Behavior	69
X. Prey Catching	70
XI. Memory and Learning	70
D. Actions of Antipsychotics on Induced Behavioral Patterns	71
I. Stimulant-Induced Excitation Patterns	71
II. Tryptamine-Induced Convulsion	73
III. Withdrawal Syndrome	74
IV. Topical Brain Stimulation	74
V. Self-Stimulation	75
VI. Rotational Model	75
VII. Brain Lesions	76
E. Side-Effects Following Acute and Chronic Administration and Tolerance Phenomena	76
F. Conclusions	80
References	81

CHAPTER 5

Testing Antipsychotic Drug Effects with Operant Behavioral Techniques.

E. LEHR

A. General Advantages of Operant Procedures for the Demonstration of Behavioral Drug Effects	89
--	----

B. Operant Procedures for Evaluating Antipsychotic Drug Actions	89
I. Active Avoidance Tests	89
II. Other Operant Procedures	91
C. Value of Operant Techniques for Detecting Antipsychotic Drug Effects	92
D. Summary	93
References	93

CHAPTER 6

Stereotyped Behavior and Its Relevance for Testing Neuroleptics.

A. RANDRUP, B. KJELLBERG, E. SCHIØRRING, J. SCHEEL-KRÜGER, R. FOG,
and I. MUNKVAD

A. Similarities and Differences Between Endogenous Psychoses and States Induced by Amphetamines in Man or Animals	97
I. Amphetamine Psychosis and Endogenous Psychoses	97
II. Comparison of Animal and Human Data	100
B. Relevance of Stereotypies in Testing Antipsychotic Drugs	101
References	104

CHAPTER 7

Neurophysiologic Properties of Neuroleptic Agents in Animals. I. JURNA.

With 14 Figures

A. Pre- and Postsynaptic Action of Antipsychotic Drugs	111
B. Spinal Neurones and Descending Pathways	115
C. Presence of Monoamines in the Brain Stem	120
I. Arousal	121
II. Analgesia and Nociceptive Reflexes	123
III. Seizure Activity	125
IV. Vomiting, Swallowing	126
D. Nigro-Neostriatal System	127
I. DA as a Transmitter	127
II. The Neuronal Feedback Loop and Self-Inhibition	131
III. Spinal Motor Activity	135
E. Mesolimbic System	141
F. Locus Coeruleus and Other Brain Stem Nuclei: Ascending Pathways	142
G. Cyclic-AMP	145
H. Concluding Remarks	150
References	150

CHAPTER 8

Antipsychotics: Neurophysiological Properties (in Man). J. ROUBICEK.

With 14 Figures

A. Future Prospects	187
-------------------------------	-----

B. Summary	190
References	190

CHAPTER 9

Biochemical Effects of Neuroleptic Drugs. G. BARTHOLINI and K.G. LLOYD. With 2 Figures

A. Introduction	193
B. General Biochemical Features of Neuroleptic Drugs	193
C. Effects of Neuroleptic Drugs in Discrete Brain Structures	196
I. Extrapyramidal System	196
1. Acetylcholine	196
2. GABA	197
3. Neuroleptic-Induced Feedback Activation of DA Neurons: Possible Role of ACh and GABA	198
4. Effects of Repeated Administration of Neuroleptics	200
5. Functional Correlates of Neuroleptic-Induced Biochemical Alterations	201
II. Limbic System	201
1. Acetylcholine	201
2. GABA	202
3. Repeated Administration of Neuroleptics: Effects in Limbic System	203
D. Atypical Neuroleptics	204
References	205

CHAPTER 10

Biochemical Effects (in Men). M. ACKENHEIL. With 2 Figures

A. Introduction	213
B. Biochemical Findings in Urine	215
C. Biochemical Findings in Blood	216
D. Biochemical Findings in CSF	218
E. Conclusions	220
References	220

CHAPTER 11

Toxicology of Antipsychotic Agents. F. LEUSCHNER, W. NEUMANN, and R. HEMPEL

A. Introduction	225
B. Butyrophenones	226
I. General	226
II. Animals	226

1. Acute Toxicity	226
2. Subchronic Toxicity	227
3. Chronic Toxicity	227
4. Fertility	231
5. Teratology	231
6. Perinatal and Postnatal Toxicity	232
III. Human Subject	232
1. Acute Toxicity	232
2. Teratology	232
3. Perinatal and Postnatal Toxicity	233
IV. Mutagenic Activity	233
V. Discussion of Side-Effects	233
C. Phenothiazines	234
I. General	234
II. Animal	234
1. Acute Toxicity	234
2. Subchronic Toxicity	237
3. Chronic Toxicity	239
4. Fertility	240
5. Teratology	241
6. Perinatal and Postnatal Toxicity	241
III. Man	242
1. Acute Toxicity	242
2. Fertility	242
3. Teratology	243
4. Perinatal and Postnatal Toxicity	243
IV. Mutagenic Activities	243
V. Carcinogenicity	244
VI. Physical Dependence	244
VII. Discussion of Side-Effects	244
D. Reserpine	246
I. General	246
II. Animals	247
1. Acute Toxicity	247
2. Subchronic Toxicity	247
3. Chronic Toxicity	248
4. Fertility	249
5. Teratology	249
6. Perinatal and Postnatal Toxicity	249
III. Man	250
1. Acute Toxicity	250
2. Teratology	251
3. Perinatal and Postnatal Toxicity	251
IV. Carcinogenicity	251
V. Discussion of Side-Effects	251
References	253

CHAPTER 12

Clinical Pharmacology (Pharmacokinetics). B. MÜLLER-OERLINGHAUSEN

A. Introduction	267
B. Phenothiazines and Thioxanthenes	267
I. Chlorpromazine, Levomepromazine	267
1. Methods for Assessment of Chlorpromazine Concentration in Biological Fluids	267
2. Pharmacokinetics of CPZ in Man	268
II. Phenothiazines with Piperidine Side-Chain (Thioridazine, Mesoridazine)	272
1. Methods for Assessment of Thioridazine Concentration in Biological Fluids	272
2. Pharmacokinetics of Thioridazine and Mesoridazine in Man	272
III. Phenothiazines with Piperazine Side-Chain (Perazine, Butaperazine, Perphenazine, Fluphenazine)	274
1. Methods for Assessment of Plasma Concentrations	274
2. Pharmacokinetics of Piperazine Side-Chain Phenothiazines in Man	274
IV. Pharmacokinetics of Thioxanthenes in Man	276
C. Pharmacokinetics of Clozapine and Loxapine in Man	277
D. Pharmacokinetics of Butyrophenones in Man	277
References	278

CHAPTER 13

Metabolism and Kinetics. U. BREYER-PFAFF. With 6 Figures

A. Introduction	287
B. Phenothiazines and Thioxanthenes	287
I. Kinetics in Animals	287
1. Absorption	287
2. Distribution	288
3. Elimination	288
II. Extent of Biotransformation in Vivo	289
III. Metabolic Pathways	290
1. Reactions at the Ring System	290
2. Reactions at the C-2 Substituent	292
3. Reactions at the N-10 Side Chain	293
4. Combinations of Reactions	295
C. Clozapine	295
I. Kinetics in Animals	295
II. Metabolism	296
D. Butyrophenones and Diphenylbutylpiperidine Derivatives	296
I. Kinetics in Animals	296
II. Metabolism	298
E. Reserpine	298
References	298

CHAPTER 14

Psychometric and Psychophysiological Actions of Antipsychotics in Men. W. JANKE

A. Introduction	305
I. Aims of the Review	305
B. Methodological Problems in Measuring the Effects of Antipsychotic Drugs on Behavioral and Psychophysiological Parameters	305
I. Selection of Indicators	305
II. Selection of Situational Conditions	307
III. Selection of Subjects	307
IV. Time Course of Action	307
C. Review of Antipsychotic Drugs on Different Areas of Psychological Functioning	308
I. Effects of Antipsychotic Drugs on Perception	308
1. Assessment Approaches	308
2. Determination of Thresholds	308
II. Effects of Antipsychotic Drugs on Thinking and Intelligence (Cognitive Processes)	311
1. Assessment Approaches	311
2. General Intelligence Tests	311
3. Reasoning	312
4. Word Fluency	312
5. Verbal Thinking	312
6. Conclusions on the Effects of Antipsychotic Drugs on Cognitive Processes	312
III. Learning	313
1. Assessment Approaches	313
2. Verbal Learning	313
3. Classical Conditioning	313
4. Operant Conditioning	313
5. Conclusions Concerning the Effects of Antipsychotic Drugs on Learning	314
IV. Memory Processes	314
V. Effects of Antipsychotic Drugs on Psychomotor Performance	314
1. Assessment Approaches	314
2. Psychomotor Speed	314
3. Sensorimotor Speed	316
4. Complex Psychomotor and Sensory Coordination	317
5. Finger, Hand, and Arm Dexterity	318
6. Finger and Hand Steadiness	318
7. Precision of Small Movements of Fingers, Hands, and Arms	318
8. Other Types of Psychomotor Abilities	318
9. Conclusions About the Effects of Antipsychotic Drugs on Psychomotor Abilities	320
VI. Concentration and Vigilance	320
1. Assessment Approaches	320
2. Vigilance	320

3. Concentration as Measured by Coding Tests (Digit Symbol Test)	321
4. Concentration Measured by Continuous Arithmetic Calculations	321
5. Concentration Measured by Cancellation Tests	321
6. Conclusions Concerning the Effects of Antipsychotic Drugs on Concentration and Vigilance	321
VII. Effects of Antipsychotic Drugs on Psychophysiological Parameters	322
1. Problems of Psychophysiological Measures	322
2. Measures of Central Nervous System	324
3. Autonomic Nervous System Measures	326
VIII. Emotional Processes	327
1. Assessment Approaches	327
2. Emotional Stability	328
3. Anxiety	329
IX. Motivational Processes	329
1. Assessment Approaches	329
2. Activation	330
3. Other Motivational Aspects	330
References	332

CHAPTER 15

Endocrine Effects of Neuroleptics. F. G. SULMAN and Y. GIVANT. With 3 Figures

A. History	337
B. Psychotherapeutic Drugs Affecting the Endocrine System	338
I. Phenothiazines	338
II. Butyrophenones	339
III. Rauwolfia Derivatives	340
IV. Benzodiazepines	341
V. Barbiturates	341
VI. Lithium	341
VII. Thalidomide	342
VIII. Antidepressants	342
IX. Hydroxyzine	343
X. Ergot Derivatives	343
C. Mechanisms of Endocrine Effects	343
I. The Mediator Theory	343
II. The Tropin Balance Theory	343
III. The Steroid Receptor Theory	346
D. Conclusions	346
References	346

Antidepressants: Chemistry (Structure and Effectiveness)

CHAPTER 16

Chemistry (Structure and Activity). F. J. Zeelen

A. Thymoleptics	352
I. Imipramine	352

II. Imipramine Analogs	353
III. Search for the "Active" Conformation of Imipramine and Its Analogs	355
IV. Further Exploration of Structure-Activity Relationships	358
V. Compounds Found in Screening	359
VI. Search for Compounds with Greater Specificity	360
VII. Compounds with a Mechanism of Action Different From that of Imipramine and Its Analogs	361
B. Conclusion	362
References	362

CHAPTER 17

Monoamine Oxidase Inhibitors as Antidepressants. N.S. KLINE and T.B. COOPER.
With 3 Figures

A. Introduction	369
B. Pharmacology — Background	370
I. Pharmacology of MAOIs	370
II. Function	371
III. Structure and Biologic Action	372
IV. Mode of Action	373
V. MAOIs Used Clinically	374
VI. Biochemical Markers — Usefulness in Practice	375
VII. Acetylation Phenotype	376
C. Evaluation of MAOI Antidepressant Efficacy	376
I. Experimental Design Problem	376
1. Spontaneous Remission	376
II. Controlled and Open Studies	377
III. Time Lapse Before Response	377
D. Practicum For Clinical Use	377
I. How to Select Patients for a MAOI	377
II. Patient Compliance	378
III. When to Use a Monoamine Oxidase Inhibitor	378
IV. Secondary Causes of Depression	379
V. Indications for the Monoamine Oxidase Inhibitors	380
E. Use in Phobic Anxiety	381
F. Achievers' Depression	381
I. Posology	382
II. Toxicity and Side Effects	382
III. Interactions	383
1. With Tricyclic Antidepressants	384
2. With Narcotic Analgesics	385
3. With Insulin	385
4. With Other Prescription Medications	385
5. With Over-the-Counter Medications	385
G. Potential for Drug Abuse	386
I. Behavioral Toxicity	386

H. Management of Overdosage and Side Effects 387

 I. Summary 393

References 393

CHAPTER 18

Tricyclic Antidepressants: General Pharmacology. I. MØLLER NIELSEN.

With 1 Figure

A. Introduction 399

B. Behavioral Effects 399

C. Interaction with Other Drugs 400

D. Interaction with Biogenic Amines 403

E. Amine Uptake Inhibition 405

F. Cardiovascular Effects 408

G. Concluding Remarks 409

References 410

CHAPTER 19

Neurophysiological Properties (in Animals). G. GOGOLÁK

A. Tricyclic Antidepressants (ADs) 415

 I. Effects of ADs on the Electrical Activity of the Brain 415

 II. Actions of ADs on the Excitability of the CNS 417

 III. Action of ADs on the EEG Arousal Response 419

 IV. Drug-Interaction Studies on ADs 420

 V. Additional Neurophysiological Studies on the Effects of ADs 424

B. Monoamine Oxidase Inhibitors (MAOIs) 425

 I. Effects of MAOIs on the Electric Activity of the Brain 425

 II. Additional Neurophysiological Results on the Effects of MAOIs 426

C. Concluding Remarks 428

References 428

Supplementary References 435

CHAPTER 20

Clinical Neurophysiological Properties of Antidepressants. T. M. ITIL and

C. SOLDATOS. With 20 Figures

A. Introduction 437

B. EEG Classification of Psychotropic Drugs 437

C. Method of EEG Analysis 441

D. EEG Findings in Depression 441

E. EEG Findings with Antidepressants 442

 I. Drugs Commonly Used as Antidepressants 442

 1. Tricyclic Antidepressants 443

 2. MAO Inhibitors 450

3. Inorganic Salts	453
4. Miscellaneous Antidepressants	454
II. Drugs Belonging to Other Classes but Having Some Antidepressant Properties	455
1. Neuroleptics with Antidepressant Properties	455
2. Psychostimulants	456
III. Drugs Predicted as Antidepressant Based on their CEEG Profiles	456
1. Drugs Predicted by Animal Pharmacology as Antidepressants, and Confirmed Based on CEEG Profiles	456
2. Drugs Predicted to be Antidepressants by CEEG Alone, But Not by Animal Pharmacology	459
F. Summary and Conclusion	464
References	466

CHAPTER 21a

Biochemical Effects of Antidepressants in Animals. F. SULSER and P.L. MOBLEY.
With 3 Figures

A. Introduction	471
B. Monoamine Oxidase Inhibitors	471
I. Multiple Forms of MAO and Selective MAO Inhibitors	471
II. Physiologic Consequences of MAO Inhibition	472
C. Tricyclic Antidepressants and Other Drugs Which Affect Monoaminergic Systems in Brain	473
I. Effects of Tricyclic Antidepressants on MAO Activity	473
II. Blockade by Tricyclic Antidepressants of the Uptake of Biogenic Amines	474
III. Interaction of Tricyclic Antidepressants with Other Drugs	477
IV. Effect of Tricyclic Antidepressants Following Their Prolonged Administration on Adaptive Presynaptic Regulation	479
V. Miscellaneous Biochemical Effects of Antidepressant Drugs	479
D. Effect of Antidepressant Drugs on the Sensitivity of the NE-Receptor-Coupled Cyclic AMP Generating System in the Limbic Forebrain and in Other Structures of the Brain	481
References	484

CHAPTER 21b

Biochemical Effects of Antidepressants in Man. G. LANGER and M. KAROBATH

A. General Introduction	491
B. Biochemical Effects of Antidepressants as Reflected in the Urine	492
I. Introduction	492
II. Effects of Tricyclics and MAO Inhibitors	492
III. Discussion	493
C. Biochemical Effects of Antidepressants as Reflected in the Blood	493
I. Introduction	493
II. Effects of Tricyclics and MAO Inhibitors	494
III. Discussion	495

D. Biochemical Effects of Antidepressants as Reflected in the CSF	495
I. Introduction	495
II. Effects of Tricyclics, MAO Inhibitors, and Precursors of Biogenic Amines	497
III. Discussion	499
E. General Discussion	499
References	500

CHAPTER 21c

Drug-Induced Alterations in Animal Behavior as a Tool for the Evaluation of Antidepressants: Correlation with Biochemical Effects. A. DELINI-STULA.

With 10 Figures

A. Introduction	505
B. Amine-Depleted Animals as a Model for the Study of Antidepressants, Correlations with Biochemical Effects	505
I. Parameters Used for the Determination of Antidepressant Effects in Amine-Depleted Animals	506
C. Drug-Induced Behaviors Implicating Aminergic Stimulation in the Evaluation of Antidepressants	514
I. Behavioral Responses Induced by Indirect Stimulation of Catecholaminergic Receptors	514
II. Behavioral Responses Induced by Direct Stimulation of Monoaminergic Receptors	517
III. Behavioral Response Related to Serotonergic Stimulation	518
D. Final Conclusion and Remarks	519
References	521

CHAPTER 22

Toxicology of Antidepressant Drugs. P. THOMANN and R. HESS. With 1 Figure

A. Introduction	527
B. Monoamine Oxidase Inhibitor	527
I. Animal Toxicity	527
1. General Toxicology	527
2. Interaction Experiments	528
II. Intoxication in Man	529
1. Effects of Acute Overdose	529
2. Treatment of Acute MAO Inhibitor Overdose	530
3. Chronic Toxicity of MAO Inhibitors	530
C. Tricyclic Antidepressants	530
I. Animal Toxicity	530
1. General Toxicology	530
2. Interaction Experiments	532
3. Cardiovascular Effects	534
4. Induction of Myeloid Body Formation	535

II. Teratology	538
III. Intoxication in Man	540
1. Effects of Acute Overdose	540
2. Treatment of Tricyclic Antidepressant Overdose	542
D. Conclusions	543
References	544

CHAPTER 23

Metabolism of Antidepressants. M. H. BICKEL

A. Introduction	551
B. Dibenzazepines	552
I. Imipramine and Its Therapeutically Used Metabolites	552
II. Derivatives of Imipramine	559
1. Chlorimipramine	559
2. Trimepramine	559
3. Lofepramine	560
4. Ketipramine	560
C. Dibenzocycloheptadienes (Amitriptyline, Nortriptyline)	560
D. Other Antidepressants	563
1. Noxiptiline	563
2. Opipramol	563
3. Protriptyline	563
4. Proheptatriene	565
5. Intriptyline	565
6. Doxepine	565
7. Prothiadene	566
8. Melitracene	566
9. Dimethacrine	566
10. Maprotiline	566
11. Dibenzepine	566
12. Miscellaneous Antidepressants	567
References	567

CHAPTER 24

Physiological and Psychological Effects of Antidepressants in Man.

M. LADER and S. BHANJI

A. Introduction	573
B. Central Physiological Effects	573
C. Peripheral Physiological Effects	575
I. Skin Conductance	575
II. Finger Tremor	576
III. Pupil Diameter	576
IV. Cardiovascular Changes	576
V. Salivation Rate	577

D. Psychological Effects 578

E. Conclusions 580

References 581

CHAPTER 25

Pharmacology and Toxicology of Lithium. M. SCHOU

A. Human Data, Animal Data, in Vitro Data 583

B. Pharmacokinetics 583

C. Renal Elimination and Mechanism of Poisoning 584

D. Adverse Effects 585

 I. Neuromuscular System 585

 II. Mind 585

 III. Heart 585

 IV. Thyroid 585

 V. Kidneys 585

 VI. Skin 586

 VII. Body Weight 586

 VIII. Edema 586

E. Teratogenicity 586

F. Lactation 587

G. Interaction with Other Drugs 587

H. Literature 587

References 587

CHAPTER 26

**Antipsychotics and Experimental Seizure Models. R. KRETZSCHMAR and
H.J. TESCHENDORF**

A. Introduction 591

B. Neuroleptics 591

 I. Tricyclic Compounds 592

 1. Clorpromazine 592

 2. Other Tricyclic Neuroleptics 598

 II. Butyrophenos and Diphenylbutylpiperidines 602

C. Reserpine 602

D. Influence of Neuroleptics and Reserpine on the Effects of Anticonvulsant
 Drugs 616

E. Conclusions 617

References 618

Author Index 623

Subject Index 713